Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25271320 | 1.00 | ADRA1D (0.49) | ADRA1DADRA1BADRA1ADPP4CYP3A4 | |
| SCHEMBL25600253 | 0.84 | HTR2A (0.44) | SUV39H2 | |
| SCHEMBL25219479 | 0.75 | HCRTR1 (0.37) | ADRA1DADRA1BADRA1A | |
| SCHEMBL30533986 | 0.75 | HCRTR1 (0.37) | ADRA1DADRA1BADRA1A | |
| SCHEMBL25261654 | 0.75 | HCRTR1 (0.37) | ADRA1DADRA1BADRA1A | |
| SCHEMBL25600268 | 0.71 | S100B (0.44) | ADRA1DADRA1BADRA1A | |
| SCHEMBL25681118 | 0.70 | KDM4E (0.41) | KCNH2 | |
| SCHEMBL25599841 | 0.70 | KCNH2 (0.36) | DPP4KCNH2 | |
| SCHEMBL30039825 | 0.70 | LMNA (0.49) | — | |
| SCHEMBL30533920 | 0.69 | ALDH1A1 (0.52) | DPP4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | ADRA1D 4695/4885ADRA1B 4304/4885ADRA1A 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.